The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.